Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Oseltamivir AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
31 results
  • The association between treatment with heparin and survival in patients with Covid-19. [Journal Article]
    J Thromb Thrombolysis. 2020 May 31 [Online ahead of print]Ayerbe L, Risco C, Ayis S
  • This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temper…
  • Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence. [Review]
    Int J Clin Pract. 2020 May 27 [Online ahead of print]Yousefifard M, Zali A, … Safari S
  • CONCLUSIONS: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials.
  • Antivirals for COVID-19. [Journal Article]
    Cleve Clin J Med. 2020 May 14 [Online ahead of print]Srinivas P, Sacha G, Koval C
  • Drugs targeting RNA respiratory viruses has resulted in few effective therapies, highlighting challenges for antivirals to treat COVID-19. Several antivirals are being investigated for symptomatic COVID-19 but no definitive data support their clinical use. Remdesivir, with good in vitro activity against SARS-CoV2, appeared to result in favorable outcomes for hospitalized patients in a compassiona…
  • Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran. [Case Reports]
    Respir Med Case Rep. 2020 May 13 [Online ahead of print]Taghizadieh A, Mikaeili H, … Valizadeh H
  • We reported a 33-year-old female case with novel coronavirus disease 2019 (COVID-19) accompanied by Acute tubular necrosis (ATN). She had a gestational age of 34 weeks. The patient referred to treatment clinic for COVID-19 in Imam Reza hospital of Tabriz (Iran) after having flu-like symptoms. In radiologic assessment, ground glass opacity (GGO) with consolidation was found in upper right lobe. Lo…
  • A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? [Editorial]
    J Virus Erad. 2020 Apr 30; 6(2):45-51.Pilkington V, Pepperrell T, Hill A
  • CONCLUSIONS: Favipiravir demonstrates a favourable safety profile regarding total and serious AEs. However, safety concerns remain: hyperuricaemia, teratogenicity and QTc prolongation have not yet been adequately studied. Favipiravir may be safe and tolerable in short-term use, but more evidence is needed to assess the longer-term effects of treatment. Given the limitations of the evidence and unresolved safety concerns, caution is warranted in the widespread use of favipiravir against pandemic COVID-19.
  • Report of 5 nurses infecting COVID-19 during patient care: case Series. [Editorial]
    New Microbes New Infect. 2020 May 13 [Online ahead of print]Gheysarzadeh A, Sadeghifard N, … Tavan H
  • CONCLUSIONS: This study showed that regardless of self caring, the nurses were exposed to COVID-19. Because at the the beginning of SARS-CoV-2 outbreak in Iran, there were no special protection against this infection.Therfore they were at risk for the COVID-19.This study also reported that receiving the necessary care and treatment at home was a good experience for nurses that can be used in some cases.
  • An Update on Current Therapeutic Drugs Treating COVID-19. [Review]
    Curr Pharmacol Rep. 2020 May 11 [Online ahead of print]Wu R, Wang L, … Kong AN
  • The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control …
  • A global treatments for coronaviruses including COVID-19. [Review]
    J Cell Physiol. 2020 May 11 [Online ahead of print]Yousefi B, Valizadeh S, … Eslami M
  • In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle Eas…
  • Outbreak of COVID-19 infection in children: fear and serenity. [Review]
    Eur Rev Med Pharmacol Sci. 2020 04; 24(8):4572-4575.Pavone P, Ceccarelli M, … Nunnari G
  • The recent outbreak of SARS-CoV-2 greatly involves the resources of the global healthcare system, as it affects newborns, adults, and elders. This infection runs in three major stages: a mild cold-like illness, a moderate respiratory syndrome and a severe acute interstitial pneumonia. SARS-CoV-2 infection seems to have a more benign evolution in children. As a matter of fact, low susceptibility a…
  • Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. [Journal Article]
    J Biomol Struct Dyn. 2020 May 15 [Online ahead of print]Al-Khafaji K, Al-Duhaidahawi D, Taskin Tok T
  • SARS-CoV-2 is a new generation of coronavirus, which was first determined in Wuhan, China, in December 2019. So far, however, there no effective treatment has been found to stop this new generation of coronavirus but discovering of the crystal structure of SARS-CoV-2 main protease (SARS-CoV-2 Mpro) may facilitate searching for new therapies for SARS-COV-2. The aim was to assess the effectiveness …
  • A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case. [Case Reports]
    Infect Disord Drug Targets. 2020 Apr 29 [Online ahead of print]Ghiasvand F, Miandoab SZ, … Alinaghi SAS
  • After the initial Wuhan outbreak in the end of December 2019, many new cases were found in other provinces of China and also many other countries over the world, including South Korea, Italy, Iran, Japan, and 68 other countries. We presented a 61-year-old woman with a history of diabetes mellitus was referred to the emergency department of a referral hospital in Tehran, Iran. The patient presente…
  • Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. [Journal Article]
    JAMA. 2020 Apr 13 [Online ahead of print]Sanders JM, Monogue ML, … Cutrell JB
  • CONCLUSIONS: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
  • Delayed Initiation of Remdesivir in a COVID-19-Positive Patient. [Case Reports]
    Pharmacotherapy. 2020 Apr 13 [Online ahead of print]Hillaker E, Belfer JJ, … Dumkow LE
  • We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40-year-old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID-19) symptoms including dry…
  • Clinical trials on drug repositioning for COVID-19 treatment. [Journal Article]
    Rev Panam Salud Publica. 2020; 44:e40.Rosa SGV, Santos WC
  • The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-…
  • The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China. [Case Reports]
    Pediatr Pulmonol. 2020 06; 55(6):E6-E9.Lin J, Duan J, … Dai J
  • In December 2019, COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbroke in Wuhan, the capital city of Hubei province, China. The disease rapidly spread to other areas in China due to a huge population movement during the New Year Festival. Here, a 7-year-old child with SARS-CoV-2 infection in Chongqing, outside of Wuhan, Hubei province, was reported. This case s…
  • [Potential antiviral therapeutics for 2019 Novel Coronavirus]. [Journal Article]
    Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12; 43(3):170-172.Li H, Wang YM, … Cao B
  • The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in…
  • Critical care management of adults with community-acquired severe respiratory viral infection. [Review]
    Intensive Care Med. 2020 02; 46(2):315-328.Arabi YM, Fowler R, Hayden FG
  • With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17-53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle Ea…
  • [Potential antiviral therapeutics for 2019 Novel Coronavirus]. [Journal Article]
    Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 05; 43(0):E002.Li H, Wang YM, … Cao B
  • The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used …
  • Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. [Review]
    Presse Med. 2011 Dec; 40(12 Pt 2):e561-8.Luyt CÉ, Combes A, … Chastre J
  • The acute respiratory distress syndrome (ARDS) can be induced by viral diseases, with two virus types being responsible: respiratory viruses that cause community-acquired viral pneumonia and Herpesviridae that cause nosocomial viral pneumonia. Among the respiratory viruses that can affect the lung and cause ARDS, pandemic viruses head the list, with influenza viruses H5N1 and H1N1 2009 being the …
New Search Next